The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers

Abstract

Psoriasis (PSO) and Atopic dermatitis (AD) are common inflammatory skin diseases that affect people of all ages globally. They negatively impact the quality of life (QoL) of patients in health-related aspects such as physical, psychological and mental functioning. Here, we conducted a review of studies relating to candidate biomarkers and indicators associated with QoL impairment in PSO and AD. Data research was performed using PUBMED and SCOPUS databases from inception to September 2022. Most of the included studies reported genomic or proteomic biomarkers associated with disease activity and QoL outcomes. Sociodemographic, clinical and therapeutic factors have also been implicated in deterioration of life quality in these patients. The inclusion of clinical characteristics, QoL impairment and co-diagnosis should be considered in drug development programs, since processing biomarkers based on an increased number of features in addition to drug class and disease will intensify the value of the biomarker itself, thereby maximizing the future clinical utility as a stratification tool.

Keywords: atopic dermatitis; biomarkers; psoriasis; quality of life.

Figure 1

(a) Representative clinical image of a patient with plaque psoriasis; (b) representative clinical image of a patient with atopic dermatitis.

Figure 2

A simplified overview of non-histaminergic itch in PSO and AD. Abbreviations: AMP, antimicrobial peptides; DC, dendritic cell; FLG, filaggrin; IFN-γ, interferon-gamma; IL, interleukin; K, keratinocyte; OP, opioids; Mrgprx, Mas-related G-protein coupled receptor X; NK-1R, neurokinin 1 receptor; OPR, opioid receptor; OSMR, oncostatin M receptor; Th, T helper; TNF-α, tumor necrosis factor-alpha; TRPA1, transient receptor potential vanilloid 1; TRPV1, transient receptor potential ankyrin 1; TSLP, thymic stromal lymphopoietin.